SCHEMBL24322185

SCHEMBL24322185

CCN1CCN(c2ccc(Nc3ncc(F)c(-c4sc5c(nc(C)n5C(C)C)c4C)n3)nn2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 17/20 0.75
CDK4 P11802 15/20 0.75
CDK6 Q00534 10/20 0.74
CCNA2 P20248 2/20 0.51
CDK2 P24941 2/20 0.51
CCND3 P30281 2/20 0.51
CIT O14578 1/20 0.51
GAK O14976 1/20 0.51
DYRK3 O43781 1/20 0.51
CCNT1 O60563 1/20 0.51
STK16 O75716 1/20 0.51
CCNK O75909 1/20 0.51
STK10 O94804 1/20 0.51
PRKD3 O94806 1/20 0.51
ABCB11 O95342 1/20 0.51
MAP4K4 O95819 1/20 0.51
CCNE2 O96020 1/20 0.51
EGFR P00533 1/20 0.51
NTRK1 P04629 1/20 0.51
PRKCB P05771 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29515159 0.90 CCND1 (0.68) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL24322186 0.90 CCND1 (0.68) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL29515160 0.89 CCND1 (0.75) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL24322997 0.89 CCND1 (0.75) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL29514918 0.88 CCND1 (0.84) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL24322347 0.88 CCND1 (0.84) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL29514967 0.85 CCND1 (1.00) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL24322192 0.85 CCND1 (1.00) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL25284830 0.85 CCND1 (1.00) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL29515035 0.85 CCND1 (1.00) CCND1CDK4CDK6CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 US disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK1, CDK3 CCND1 46/4885CDK4 12/4885CDK6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.